Silo Pharma, Inc. (SILO) 10-Year Financial Performance & Capital Metrics

SILO • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutSilo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.Show more

Revenue $72K
EBITDA -$5M -29.6%
Net Income -$4M -18.7%
EPS (Diluted) -1.19 +0.8%
Gross Margin 91.9%
EBITDA Margin -6517.86% -29.6%
Operating Margin -6526.44% -22.0%
Net Margin -6092.59% -18.7%
ROE -78.37% -74.9%
ROIC -186.68% +47.5%
Debt/Equity -
Interest Coverage -925.59 -16.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 12.2%
✓Trading at only 0.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 10 (bottom 10%)
✗Shares diluted 19.5% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y12.19%

3Y0.39%

TTM0%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-34.18%

EPS CAGR

10Y-

5Y-

3Y-

TTM22.5%

ROCE

10Y Avg-73.39%

5Y Avg-92.83%

3Y Avg-50.2%

Latest-73.95%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	-145.19K	-669.48K	847.41K	0	40.57K	0	71.26K	72.1K	72.1K	72.1K
Revenue Growth %	-0.36%	-3.61%	2.27%	-1%	-	-1%	-	0.01%	0%	0%
Cost of Goods Sold+	0	0	0	17.55K	27.39K	0	5K	5.84K	5.84K	5.84K
COGS % of Revenue	-	-	-	-	0.68%	-	0.07%	0.08%	0.08%	0.08%
Gross Profit+	-145.19K	-669.48K	847.41K	-17.55K	13.18K	0	66.26K	66.26K	66.26K	66.26K
Gross Margin %	1%	1%	1%	-	0.32%	-	0.93%	0.92%	0.92%	0.92%
Gross Profit Growth %	-8.06%	-3.61%	2.27%	-1.02%	1.75%	-1%	-	0%	0%	0%
Operating Expenses+	264.31K	443.49K	490.87K	459.83K	943.59K	2.2M	2.81M	3.69M	3.92M	4.77M
OpEx % of Revenue	-1.82%	-0.66%	0.58%	-	23.26%	-	39.44%	51.23%	54.39%	66.18%
Selling, General & Admin	167.7K	300.99K	313.37K	459.83K	864.18K	2.18M	2.27M	2.43M	3.08M	2.4M
SG&A % of Revenue	-1.16%	-0.45%	0.37%	-	21.3%	-	31.79%	33.67%	42.67%	33.34%
Research & Development	0	0	0	0	63.47K	26.25K	693.91K	1.29M	845.09K	2.37M
R&D % of Revenue	-	-	-	-	1.56%	-	9.74%	17.84%	11.72%	32.84%
Other Operating Expenses	96.61K	142.5K	177.5K	314.61K	15.94K	0	-148.5K	-20K	0	0
Operating Income+	-217.17K	-393.66K	-470.39K	-594.24K	-930.4K	-2.2M	-2.74M	-3.63M	-3.86M	-4.71M
Operating Margin %	1.5%	0.59%	-0.56%	-	-22.93%	-	-38.51%	-50.31%	-53.47%	-65.26%
Operating Income Growth %	0.13%	-0.81%	-0.19%	-0.26%	-0.57%	-1.37%	-0.25%	-0.32%	-0.06%	-0.22%
EBITDA+	-24.85K	325.66K	-1.17M	-576.69K	-950.37K	-2.4M	4.19M	-3.91M	-3.63M	-4.7M
EBITDA Margin %	0.17%	-0.49%	-1.38%	-	-23.43%	-	58.73%	-54.16%	-50.29%	-65.18%
EBITDA Growth %	0.79%	14.11%	-4.6%	0.51%	-0.65%	-1.52%	2.75%	-1.93%	0.07%	-0.3%
D&A (Non-Cash Add-back)	192.33K	719.32K	-701.1K	17.55K	0	0	0	0	0	6.18K
EBIT	-217.17K	-393.66K	356.54K	-969.46K	-950.37K	-2.4M	4.19M	-3.91M	-3.63M	-4.39M
Net Interest Income+	40.34K	49.84K	0	0	-50.73K	-257.72K	-1.83K	70.44K	393.66K	328.08K
Interest Income	40.34K	49.84K	20.48K	4.22K	12.2K	11.54K	1.21K	72.64K	398.53K	333.17K
Interest Expense	0	0	0	0	62.93K	269.27K	3.04K	2.2K	4.87K	5.08K
Other Income/Expense	-192.33K	-719.32K	826.92K	-375.22K	-82.89K	-464.55K	6.93M	-279.73K	224.51K	312.81K
Pretax Income+	-409.5K	-1.11M	356.54K	-969.46K	-1.01M	-2.67M	4.18M	-3.91M	-3.63M	-4.39M
Pretax Margin %	2.82%	1.66%	0.42%	-	-24.98%	-	58.68%	-54.19%	-50.36%	-60.93%
Income Tax+	0	0	0	0	0	0	24.88K	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1.14%	0.93%	1%	1.02%	1%
Net Income+	-409.5K	-1.11M	356.54K	-969.46K	-1.01M	-3.04M	3.9M	-3.91M	-3.7M	-4.39M
Net Margin %	2.82%	1.66%	0.42%	-	-24.98%	-	54.78%	-54.21%	-51.33%	-60.93%
Net Income Growth %	-0.09%	-1.72%	1.32%	-3.72%	-0.05%	-2%	2.29%	-2%	0.05%	-0.19%
Net Income (Continuing)	-409.5K	-1.11M	356.54K	-969.46K	-1.01M	-2.67M	4.16M	-3.91M	-3.63M	-4.39M
Discontinued Operations	0	0	0	0	0	-371.25K	-253.37K	-1.16K	-69.6K	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.40	-1.11	0.50	-0.99	-1.24	-2.35	1.30	-1.71	-1.20	-1.19
EPS Growth %	-0.03%	-1.77%	1.45%	-2.98%	-0.25%	-0.9%	1.55%	-2.32%	0.3%	0.01%
EPS (Basic)	-0.40	-1.11	0.50	-0.99	-1.24	-2.35	1.32	-1.71	-1.20	-1.19
Diluted Shares Outstanding	1.01M	1M	1.04M	982.03K	842.29K	1.32M	1.92M	2.28M	3.08M	3.68M
Basic Shares Outstanding	1.01M	1M	1M	982.03K	842.29K	1.32M	1.9M	2.28M	3.08M	3.68M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	758.72K	664.73K	1.64M	625.98K	493.85K	1.43M	10.4M	11.57M	7.68M	7.11M
Cash & Short-Term Investments	722.76K	579.21K	294.59K	564.97K	121.15K	1.13M	10.26M	11.37M	7.67M	7.08M
Cash Only	722.76K	579.21K	294.59K	336.68K	111.75K	1.13M	9.84M	11.37M	3.52M	3.91M
Short-Term Investments	0	0	0	228.29K	9.39K	200	420K	3.12K	4.14M	3.17M
Accounts Receivable	15.92K	58.55K	0	0	200K	23.5K	0	66.01K	0	0
Days Sales Outstanding	-40.03	-31.92	-	-	1.8K	-	-	334.16	-	-
Inventory	0	0	0	26.97K	156.37K	33.48K	0	0	0	0
Days Inventory Outstanding	-	-	-	560.98	2.08K	-	-	-	-	-
Other Current Assets	0	0	1.35M	0	0	0	145.32K	0	15.97K	30.96K
Total Non-Current Assets+	1.69M	634.87K	1.32M	229.44K	0	0	87.87K	70.82K	64.98K	300.36K
Property, Plant & Equipment	0	0	0	0	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	29.44K	0	0	0	0	0	241.22K
Long-Term Investments	1.69M	634.87K	1.32M	200K	0	0	61.21K	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	26.66K	70.82K	64.98K	59.15K
Total Assets+	2.45M	1.3M	1.64M	855.42K	493.85K	1.43M	10.49M	11.64M	7.75M	7.41M
Asset Turnover	-0.06x	-0.52x	0.52x	-	0.08x	-	0.01x	0.01x	0.01x	0.01x
Asset Growth %	-0.12%	-0.47%	0.26%	-0.48%	-0.42%	1.89%	6.35%	0.11%	-0.33%	-0.04%
Total Current Liabilities+	90.76K	53.1K	38.34K	47.98K	116.74K	141.72K	490.04K	436.32K	775.59K	1.66M
Accounts Payable	90.76K	53.1K	38.34K	25.63K	54.86K	127.07K	417.94K	364.22K	703.49K	1.58M
Days Payables Outstanding	-	-	-	533.07	731.17	-	30.49K	22.77K	43.98K	99.03K
Short-Term Debt	0	0	0	22.34K	61.88K	14.65K	0	0	0	0
Deferred Revenue (Current)	0	0	0	-25.63K	-116.74K	0	72.1K	72.1K	72.1K	72.1K
Other Current Liabilities	0	0	0	0	116.74K	0	0	0	0	0
Current Ratio	8.36x	12.52x	42.81x	13.05x	4.23x	10.07x	21.23x	26.52x	9.90x	4.29x
Quick Ratio	8.36x	12.52x	42.81x	12.49x	2.89x	9.83x	21.23x	26.52x	9.90x	4.29x
Cash Conversion Cycle	-	-	-	-	3.15K	-	-	-	-	-
Total Non-Current Liabilities+	400K	400K	400K	400K	400K	4.25K	937.88K	865.78K	793.68K	721.58K
Long-Term Debt	0	0	0	0	0	4.25K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	400K	400K	400K	400K	400K	0	0	0	0	0
Total Liabilities	490.76K	453.1K	438.34K	447.98K	516.74K	145.97K	1.43M	1.3M	1.57M	2.38M
Total Debt+	0	0	0	22.34K	61.88K	18.9K	0	0	0	0
Net Debt	-722.76K	-579.21K	-294.59K	-314.33K	-49.88K	-1.11M	-9.84M	-11.37M	-3.52M	-3.91M
Debt / Equity	-	-	-	0.05x	-	0.01x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-1.78x	-	-	-	-	-2.35x	-	-	-
Interest Coverage	-	-	-	-	-14.79x	-8.18x	-903.93x	-1649.68x	-791.87x	-925.59x
Total Equity+	1.96M	846.51K	1.2M	407.44K	-22.89K	1.28M	9.06M	10.34M	6.18M	5.03M
Equity Growth %	-0.17%	-0.57%	0.42%	-0.66%	-1.06%	56.95%	6.08%	0.14%	-0.4%	-0.18%
Book Value per Share	1.94	0.84	1.15	0.41	-0.03	0.97	4.72	4.53	2.01	1.37
Total Shareholders' Equity	1.96M	846.51K	1.2M	407.44K	-22.89K	1.28M	9.06M	10.34M	6.18M	5.03M
Common Stock	5.06K	5.01K	5.01K	2.34K	2.36K	8.51K	9.86K	316	316	449
Retained Earnings	-400K	-400K	-470.39K	-1.64M	-2.66M	-5.76M	-3.26M	-7.17M	-10.87M	-15.26M
Treasury Stock	0	566.36K	0	0	0	0	0	0	-471.12K	0
Accumulated OCI	-364.42K	-566.36K	-1.12M	-400K	-400K	0	0	0	-6.23K	2.42K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.02M	-143.56K	-284.62K	272.64K	-794.32K	-1.16M	-2.28M	-3.5M	-3.22M	-3.83M
Operating CF Margin %	7%	0.21%	-0.34%	-	-19.58%	-	-31.97%	-48.51%	-44.72%	-53.17%
Operating CF Growth %	0.04%	0.86%	-0.98%	1.96%	-3.91%	-0.46%	-0.97%	-0.54%	0.08%	-0.19%
Net Income	-409.5K	-1.11M	356.54K	-969.46K	-1.01M	-3.04M	4.16M	-3.91M	-3.7M	-4.39M
Depreciation & Amortization	-8.14K	0	0	17.55K	0	0	0	0	0	6.18K
Stock-Based Compensation	0	0	0	0	177.96K	1.19M	0	156.05K	14.13K	0
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-674.94K	1.06M	-606.45K	1.24M	123.47K	763.26K	-7.14M	330.17K	162.78K	1.02K
Working Capital Changes	75.82K	-89.38K	-34.71K	-16.8K	-82.46K	-72.14K	704.75K	-75.29K	299.27K	551.76K
Change in Receivables	-11.29K	-44.78K	-20.36K	0	0	0	-1.21K	-4.8K	-3.59K	0
Change in Inventory	0	0	0	-26.97K	-129.39K	-15.06K	-24.96K	0	0	0
Change in Payables	88.2K	-37.66K	-14.76K	-12.71K	0	0	0	-53.72K	339.27K	0
Cash from Investing+	-875.41K	344.48K	157.57K	-250K	186.74K	39K	7.19M	86.71K	-4.15M	973.78K
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	0%	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	-977.5K	0	39K	172K	20K	0	0
Cash from Financing+	-2.25K	0	0	19.45K	382.66K	2.13M	3.79M	4.94M	-471.12K	3.24M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-2.25K	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	0	0	0	0	3
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.02M	-143.56K	-284.62K	272.64K	-794.32K	-1.16M	-2.28M	-3.5M	-3.22M	-3.83M
FCF Margin %	7%	0.21%	-0.34%	-	-19.58%	-	-31.97%	-48.51%	-44.72%	-53.17%
FCF Growth %	0.04%	0.86%	-0.98%	1.96%	-3.91%	-0.46%	-0.97%	-0.54%	0.08%	-0.19%
FCF per Share	-1.01	-0.14	-0.27	0.28	-0.94	-0.88	-1.19	-1.53	-1.05	-1.04
FCF Conversion (FCF/Net Income)	2.48x	0.13x	-0.80x	-0.28x	0.78x	0.38x	-0.58x	0.89x	0.87x	0.87x
Interest Paid	0	0	0	0	0	224	0	2.2K	4.87K	5.08K
Taxes Paid	1.75K	250	0	0	0	0	0	25.16K	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-18.92%	-79.33%	34.79%	-120.39%	-527%	-482.99%	75.49%	-40.29%	-44.81%	-78.37%
Return on Invested Capital (ROIC)	-17.46%	-39.26%	-60.01%	-89%	-6862.05%	-3355.02%	-	-	-355.62%	-186.68%
Gross Margin	100%	100%	100%	-	32.49%	-	92.98%	91.9%	91.9%	91.9%
Net Margin	282.05%	166.24%	42.07%	-	-2497.71%	-	5477.86%	-5420.86%	-5132.57%	-6092.59%
Debt / Equity	-	-	-	0.05x	-	0.01x	-	-	-	-
Interest Coverage	-	-	-	-	-14.79x	-8.18x	-903.93x	-1649.68x	-791.87x	-925.59x
FCF Conversion	2.48x	0.13x	-0.80x	-0.28x	0.78x	0.38x	-0.58x	0.89x	0.87x	0.87x
Revenue Growth	-35.54%	-361.12%	226.58%	-100%	-	-100%	-	1.18%	0%	0%

Frequently Asked Questions

Growth & Financials

Silo Pharma, Inc. (SILO) reported $0.1M in revenue for fiscal year 2024.

Silo Pharma, Inc. (SILO) grew revenue by 0.0% over the past year. Growth has been modest.

Silo Pharma, Inc. (SILO) reported a net loss of $5.1M for fiscal year 2024.

Dividend & Returns

Silo Pharma, Inc. (SILO) has a return on equity (ROE) of -78.4%. Negative ROE indicates the company is unprofitable.

Silo Pharma, Inc. (SILO) had negative free cash flow of $4.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Silo Pharma, Inc. (SILO) 10-Year Financial Performance & Capital Metrics

SILO • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

Revenue $72K
EBITDA -$5M -29.6%
Net Income -$4M -18.7%
EPS (Diluted) -1.19 +0.8%
Gross Margin 91.9%
EBITDA Margin -6517.86% -29.6%
Operating Margin -6526.44% -22.0%
Net Margin -6092.59% -18.7%
ROE -78.37% -74.9%
ROIC -186.68% +47.5%
Debt/Equity -
Interest Coverage -925.59 -16.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 12.2%
✓Trading at only 0.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 10 (bottom 10%)
✗Shares diluted 19.5% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y12.19%

3Y0.39%

TTM0%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-34.18%

EPS CAGR

10Y-

5Y-

3Y-

TTM22.5%

ROCE

10Y Avg-73.39%

5Y Avg-92.83%

3Y Avg-50.2%

Latest-73.95%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	-145.19K	-669.48K	847.41K	0	40.57K	0	71.26K	72.1K	72.1K	72.1K
Revenue Growth %	-0.36%	-3.61%	2.27%	-1%	-	-1%	-	0.01%	0%	0%
Cost of Goods Sold+	0	0	0	17.55K	27.39K	0	5K	5.84K	5.84K	5.84K
COGS % of Revenue	-	-	-	-	0.68%	-	0.07%	0.08%	0.08%	0.08%
Gross Profit+	-145.19K	-669.48K	847.41K	-17.55K	13.18K	0	66.26K	66.26K	66.26K	66.26K
Gross Margin %	1%	1%	1%	-	0.32%	-	0.93%	0.92%	0.92%	0.92%
Gross Profit Growth %	-8.06%	-3.61%	2.27%	-1.02%	1.75%	-1%	-	0%	0%	0%
Operating Expenses+	264.31K	443.49K	490.87K	459.83K	943.59K	2.2M	2.81M	3.69M	3.92M	4.77M
OpEx % of Revenue	-1.82%	-0.66%	0.58%	-	23.26%	-	39.44%	51.23%	54.39%	66.18%
Selling, General & Admin	167.7K	300.99K	313.37K	459.83K	864.18K	2.18M	2.27M	2.43M	3.08M	2.4M
SG&A % of Revenue	-1.16%	-0.45%	0.37%	-	21.3%	-	31.79%	33.67%	42.67%	33.34%
Research & Development	0	0	0	0	63.47K	26.25K	693.91K	1.29M	845.09K	2.37M
R&D % of Revenue	-	-	-	-	1.56%	-	9.74%	17.84%	11.72%	32.84%
Other Operating Expenses	96.61K	142.5K	177.5K	314.61K	15.94K	0	-148.5K	-20K	0	0
Operating Income+	-217.17K	-393.66K	-470.39K	-594.24K	-930.4K	-2.2M	-2.74M	-3.63M	-3.86M	-4.71M
Operating Margin %	1.5%	0.59%	-0.56%	-	-22.93%	-	-38.51%	-50.31%	-53.47%	-65.26%
Operating Income Growth %	0.13%	-0.81%	-0.19%	-0.26%	-0.57%	-1.37%	-0.25%	-0.32%	-0.06%	-0.22%
EBITDA+	-24.85K	325.66K	-1.17M	-576.69K	-950.37K	-2.4M	4.19M	-3.91M	-3.63M	-4.7M
EBITDA Margin %	0.17%	-0.49%	-1.38%	-	-23.43%	-	58.73%	-54.16%	-50.29%	-65.18%
EBITDA Growth %	0.79%	14.11%	-4.6%	0.51%	-0.65%	-1.52%	2.75%	-1.93%	0.07%	-0.3%
D&A (Non-Cash Add-back)	192.33K	719.32K	-701.1K	17.55K	0	0	0	0	0	6.18K
EBIT	-217.17K	-393.66K	356.54K	-969.46K	-950.37K	-2.4M	4.19M	-3.91M	-3.63M	-4.39M
Net Interest Income+	40.34K	49.84K	0	0	-50.73K	-257.72K	-1.83K	70.44K	393.66K	328.08K
Interest Income	40.34K	49.84K	20.48K	4.22K	12.2K	11.54K	1.21K	72.64K	398.53K	333.17K
Interest Expense	0	0	0	0	62.93K	269.27K	3.04K	2.2K	4.87K	5.08K
Other Income/Expense	-192.33K	-719.32K	826.92K	-375.22K	-82.89K	-464.55K	6.93M	-279.73K	224.51K	312.81K
Pretax Income+	-409.5K	-1.11M	356.54K	-969.46K	-1.01M	-2.67M	4.18M	-3.91M	-3.63M	-4.39M
Pretax Margin %	2.82%	1.66%	0.42%	-	-24.98%	-	58.68%	-54.19%	-50.36%	-60.93%
Income Tax+	0	0	0	0	0	0	24.88K	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1.14%	0.93%	1%	1.02%	1%
Net Income+	-409.5K	-1.11M	356.54K	-969.46K	-1.01M	-3.04M	3.9M	-3.91M	-3.7M	-4.39M
Net Margin %	2.82%	1.66%	0.42%	-	-24.98%	-	54.78%	-54.21%	-51.33%	-60.93%
Net Income Growth %	-0.09%	-1.72%	1.32%	-3.72%	-0.05%	-2%	2.29%	-2%	0.05%	-0.19%
Net Income (Continuing)	-409.5K	-1.11M	356.54K	-969.46K	-1.01M	-2.67M	4.16M	-3.91M	-3.63M	-4.39M
Discontinued Operations	0	0	0	0	0	-371.25K	-253.37K	-1.16K	-69.6K	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.40	-1.11	0.50	-0.99	-1.24	-2.35	1.30	-1.71	-1.20	-1.19
EPS Growth %	-0.03%	-1.77%	1.45%	-2.98%	-0.25%	-0.9%	1.55%	-2.32%	0.3%	0.01%
EPS (Basic)	-0.40	-1.11	0.50	-0.99	-1.24	-2.35	1.32	-1.71	-1.20	-1.19
Diluted Shares Outstanding	1.01M	1M	1.04M	982.03K	842.29K	1.32M	1.92M	2.28M	3.08M	3.68M
Basic Shares Outstanding	1.01M	1M	1M	982.03K	842.29K	1.32M	1.9M	2.28M	3.08M	3.68M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	758.72K	664.73K	1.64M	625.98K	493.85K	1.43M	10.4M	11.57M	7.68M	7.11M
Cash & Short-Term Investments	722.76K	579.21K	294.59K	564.97K	121.15K	1.13M	10.26M	11.37M	7.67M	7.08M
Cash Only	722.76K	579.21K	294.59K	336.68K	111.75K	1.13M	9.84M	11.37M	3.52M	3.91M
Short-Term Investments	0	0	0	228.29K	9.39K	200	420K	3.12K	4.14M	3.17M
Accounts Receivable	15.92K	58.55K	0	0	200K	23.5K	0	66.01K	0	0
Days Sales Outstanding	-40.03	-31.92	-	-	1.8K	-	-	334.16	-	-
Inventory	0	0	0	26.97K	156.37K	33.48K	0	0	0	0
Days Inventory Outstanding	-	-	-	560.98	2.08K	-	-	-	-	-
Other Current Assets	0	0	1.35M	0	0	0	145.32K	0	15.97K	30.96K
Total Non-Current Assets+	1.69M	634.87K	1.32M	229.44K	0	0	87.87K	70.82K	64.98K	300.36K
Property, Plant & Equipment	0	0	0	0	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	29.44K	0	0	0	0	0	241.22K
Long-Term Investments	1.69M	634.87K	1.32M	200K	0	0	61.21K	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	26.66K	70.82K	64.98K	59.15K
Total Assets+	2.45M	1.3M	1.64M	855.42K	493.85K	1.43M	10.49M	11.64M	7.75M	7.41M
Asset Turnover	-0.06x	-0.52x	0.52x	-	0.08x	-	0.01x	0.01x	0.01x	0.01x
Asset Growth %	-0.12%	-0.47%	0.26%	-0.48%	-0.42%	1.89%	6.35%	0.11%	-0.33%	-0.04%
Total Current Liabilities+	90.76K	53.1K	38.34K	47.98K	116.74K	141.72K	490.04K	436.32K	775.59K	1.66M
Accounts Payable	90.76K	53.1K	38.34K	25.63K	54.86K	127.07K	417.94K	364.22K	703.49K	1.58M
Days Payables Outstanding	-	-	-	533.07	731.17	-	30.49K	22.77K	43.98K	99.03K
Short-Term Debt	0	0	0	22.34K	61.88K	14.65K	0	0	0	0
Deferred Revenue (Current)	0	0	0	-25.63K	-116.74K	0	72.1K	72.1K	72.1K	72.1K
Other Current Liabilities	0	0	0	0	116.74K	0	0	0	0	0
Current Ratio	8.36x	12.52x	42.81x	13.05x	4.23x	10.07x	21.23x	26.52x	9.90x	4.29x
Quick Ratio	8.36x	12.52x	42.81x	12.49x	2.89x	9.83x	21.23x	26.52x	9.90x	4.29x
Cash Conversion Cycle	-	-	-	-	3.15K	-	-	-	-	-
Total Non-Current Liabilities+	400K	400K	400K	400K	400K	4.25K	937.88K	865.78K	793.68K	721.58K
Long-Term Debt	0	0	0	0	0	4.25K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	400K	400K	400K	400K	400K	0	0	0	0	0
Total Liabilities	490.76K	453.1K	438.34K	447.98K	516.74K	145.97K	1.43M	1.3M	1.57M	2.38M
Total Debt+	0	0	0	22.34K	61.88K	18.9K	0	0	0	0
Net Debt	-722.76K	-579.21K	-294.59K	-314.33K	-49.88K	-1.11M	-9.84M	-11.37M	-3.52M	-3.91M
Debt / Equity	-	-	-	0.05x	-	0.01x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-1.78x	-	-	-	-	-2.35x	-	-	-
Interest Coverage	-	-	-	-	-14.79x	-8.18x	-903.93x	-1649.68x	-791.87x	-925.59x
Total Equity+	1.96M	846.51K	1.2M	407.44K	-22.89K	1.28M	9.06M	10.34M	6.18M	5.03M
Equity Growth %	-0.17%	-0.57%	0.42%	-0.66%	-1.06%	56.95%	6.08%	0.14%	-0.4%	-0.18%
Book Value per Share	1.94	0.84	1.15	0.41	-0.03	0.97	4.72	4.53	2.01	1.37
Total Shareholders' Equity	1.96M	846.51K	1.2M	407.44K	-22.89K	1.28M	9.06M	10.34M	6.18M	5.03M
Common Stock	5.06K	5.01K	5.01K	2.34K	2.36K	8.51K	9.86K	316	316	449
Retained Earnings	-400K	-400K	-470.39K	-1.64M	-2.66M	-5.76M	-3.26M	-7.17M	-10.87M	-15.26M
Treasury Stock	0	566.36K	0	0	0	0	0	0	-471.12K	0
Accumulated OCI	-364.42K	-566.36K	-1.12M	-400K	-400K	0	0	0	-6.23K	2.42K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.02M	-143.56K	-284.62K	272.64K	-794.32K	-1.16M	-2.28M	-3.5M	-3.22M	-3.83M
Operating CF Margin %	7%	0.21%	-0.34%	-	-19.58%	-	-31.97%	-48.51%	-44.72%	-53.17%
Operating CF Growth %	0.04%	0.86%	-0.98%	1.96%	-3.91%	-0.46%	-0.97%	-0.54%	0.08%	-0.19%
Net Income	-409.5K	-1.11M	356.54K	-969.46K	-1.01M	-3.04M	4.16M	-3.91M	-3.7M	-4.39M
Depreciation & Amortization	-8.14K	0	0	17.55K	0	0	0	0	0	6.18K
Stock-Based Compensation	0	0	0	0	177.96K	1.19M	0	156.05K	14.13K	0
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-674.94K	1.06M	-606.45K	1.24M	123.47K	763.26K	-7.14M	330.17K	162.78K	1.02K
Working Capital Changes	75.82K	-89.38K	-34.71K	-16.8K	-82.46K	-72.14K	704.75K	-75.29K	299.27K	551.76K
Change in Receivables	-11.29K	-44.78K	-20.36K	0	0	0	-1.21K	-4.8K	-3.59K	0
Change in Inventory	0	0	0	-26.97K	-129.39K	-15.06K	-24.96K	0	0	0
Change in Payables	88.2K	-37.66K	-14.76K	-12.71K	0	0	0	-53.72K	339.27K	0
Cash from Investing+	-875.41K	344.48K	157.57K	-250K	186.74K	39K	7.19M	86.71K	-4.15M	973.78K
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	0%	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	-977.5K	0	39K	172K	20K	0	0
Cash from Financing+	-2.25K	0	0	19.45K	382.66K	2.13M	3.79M	4.94M	-471.12K	3.24M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-2.25K	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	0	0	0	0	3
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.02M	-143.56K	-284.62K	272.64K	-794.32K	-1.16M	-2.28M	-3.5M	-3.22M	-3.83M
FCF Margin %	7%	0.21%	-0.34%	-	-19.58%	-	-31.97%	-48.51%	-44.72%	-53.17%
FCF Growth %	0.04%	0.86%	-0.98%	1.96%	-3.91%	-0.46%	-0.97%	-0.54%	0.08%	-0.19%
FCF per Share	-1.01	-0.14	-0.27	0.28	-0.94	-0.88	-1.19	-1.53	-1.05	-1.04
FCF Conversion (FCF/Net Income)	2.48x	0.13x	-0.80x	-0.28x	0.78x	0.38x	-0.58x	0.89x	0.87x	0.87x
Interest Paid	0	0	0	0	0	224	0	2.2K	4.87K	5.08K
Taxes Paid	1.75K	250	0	0	0	0	0	25.16K	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-18.92%	-79.33%	34.79%	-120.39%	-527%	-482.99%	75.49%	-40.29%	-44.81%	-78.37%
Return on Invested Capital (ROIC)	-17.46%	-39.26%	-60.01%	-89%	-6862.05%	-3355.02%	-	-	-355.62%	-186.68%
Gross Margin	100%	100%	100%	-	32.49%	-	92.98%	91.9%	91.9%	91.9%
Net Margin	282.05%	166.24%	42.07%	-	-2497.71%	-	5477.86%	-5420.86%	-5132.57%	-6092.59%
Debt / Equity	-	-	-	0.05x	-	0.01x	-	-	-	-
Interest Coverage	-	-	-	-	-14.79x	-8.18x	-903.93x	-1649.68x	-791.87x	-925.59x
FCF Conversion	2.48x	0.13x	-0.80x	-0.28x	0.78x	0.38x	-0.58x	0.89x	0.87x	0.87x
Revenue Growth	-35.54%	-361.12%	226.58%	-100%	-	-100%	-	1.18%	0%	0%

Frequently Asked Questions

Growth & Financials

Silo Pharma, Inc. (SILO) reported $0.1M in revenue for fiscal year 2024.

Silo Pharma, Inc. (SILO) grew revenue by 0.0% over the past year. Growth has been modest.

Silo Pharma, Inc. (SILO) reported a net loss of $5.1M for fiscal year 2024.

Dividend & Returns

Silo Pharma, Inc. (SILO) has a return on equity (ROE) of -78.4%. Negative ROE indicates the company is unprofitable.

Silo Pharma, Inc. (SILO) had negative free cash flow of $4.8M in fiscal year 2024, likely due to heavy capital investments.